GLOPAD Paediatric Use Case: Important Considerations in Assessing the Population Representativeness of Paediatric Clinical Trials
Randomized controlled trials remain the gold standards for generating new novel medical evidence. To be meaningful the evidence generated must be generalizable to the real-world population. The generalisability of a trial is partially determined by its population representativeness, which measures the coverage of the trial participants within the real-world patient population.